Osteomyelitis

General introduction
Osteomyelitis, an inflammatory process caused by an infective microorganism and accompanied by bone destruction, has been extensively reviewed in the medical literature. [1] [2] [3] [4] [5] [6] It can occur in a confined portion of the bone or involve multiple regions, including the marrow, cortex, periosteum, and surrounding soft tissue. Osteomyelitis can be categorized based on its pathological origins, the most frequent being a local spread from a contiguous focus of infection occurring after trauma, surgery, the insertion of joint prostheses or from diabetic foot infection ( Figure 1) . 1 This form occurs most often in adults and accounts for 80% of cases. 7 Osteomyelitis of hematogenous origin, on the other hand, occurs when bone is seeded by bacteria present in blood and is found mostly in prepubertal children and in elderly patients. 1 Osteomyelitis secondary to vascular insufficiency, in which soft tissue infection in the foot spreads to bone, has also been described in populations with diabetic foot infections. 8 Beyond characterization as contiguous or hematogenous (based on the source of infection), osteomyelitis is also classified as acute or chronic based on its duration. 9 Acute osteomyelitis can be detected by histological methods 2 weeks after the onset of the disease, whereas chronic osteomyelitis is long standing, evolving over months or years, and is histologically detectable a few months after disease onset. Other classification systems for osteomyelitis include the Waldvogel and the Cierny-Mader schemes. 10, 11 The latter is used by orthopedic surgeons for treating patients with chronic osteomyelitis and combines considerations of the anatomical stages of the disease and the physiology of the patient. It applies best to long and large bones and is not very useful in classifying the disease in digits, small bones, or the skull.
Development and progression
Osteomyelitis develops when bacterial contamination and adhesion develop into infection and subsequent chronicity. Pathogenic factors that cause this chronicity can be divided into local and general factors. Local factors include the presence of foreign bodies, bone necrosis, and heavy contamination by devitalized bone fragments from trauma or surgery. Additionally, strains of bacteria may gain a survival advantage from their slow metabolic rates, ability to hide intracellularly, and the presence of a host defect in the presence of an implant. 12 Biofilm-embedded microorganisms have additional advantages, including the resistance to removal tactics, such as the use of antimicrobial or antifouling agents, shear stress, host phagocytic clearance, and host oxygen radical and protease defenses. Biofilms also have the capability to act as diffusion barriers to slow down the infiltration of some antimicrobial agents and could have the potential to detach and spread under mechanical fluid shear or through genetically mediated detachment processes. 13 General factors affecting chronicity in patients include diabetes, peripheral vascular disease, obesity, and smoking. 12 A typical route for osteomyelitis development begins with the production of pus in the medulla leading to the development of an abscess in the marrow space. This swelling presses against the outer wall of bone, compressing the blood vessels in the bone marrow and leading to localized bone death in avascular areas. Resulting reactive hyperemia is associated with increased osteoclastic activity, leading to localized bone loss and osteoporosis. Progression of this process may lead to bone necrosis and fracture of the affected bone ( Figure 2 ).
1,2
Diagnosis and treatment
Bone infections are painful and unpleasant for patients and should be treated as early as possible. Acute osteomyelitis responds to treatment with antibiotics alone, although the avascular bone necrosis and sequestrum formation that occur during chronic osteomyelitis may necessitate surgical debridement in addition to antibiotic treatment.
14 Identification of the causative agent of osteomyelitis is essential for administering effective treatment. For example, Staphylococcus aureus is the main foreign body found in chronic bacterial osteomyelitis, followed by Pseudomonas and Enterobacteriacea. 12, [15] [16] [17] [18] However, it should be noted that the successful management of most other infectious diseases by antibiotics has not yet 
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Besilesomab for imaging inflammation/infection in peripheral bone been replicated for osteomyelitis. This is not only due to the unique physiological and anatomical characteristics of bone but also due to difficulties involved in diagnosing osteomyelitis. For example, sometimes osteomyelitis manifests without signs and symptoms. Alternatively, signs and symptoms of osteomyelitis can be difficult to distinguish from other diseases such as neuropathic osteoarthropathy. 19 Moreover, the frequently concurrent existence of bone and soft tissue abnormalities complicates diagnosis of osteomyelitis, leading to false-positive and false-negative findings. Nevertheless, early and accurate diagnosis is essential for successful management of the disease, and so, much research has been undertaken to develop diagnostic molecular imaging strategies to support histological data. Such developments have been the subject of recent reviews. 9, [20] [21] [22] [23] [24] [25] For example, ultrasound, 26, 27 computed tomography (CT), 21, 22, 28 magnetic resonance imaging (MRI), [29] [30] [31] [32] optical 20 and nuclear medicine techniques 20, 23, 24, [33] [34] [35] [36] [37] have all been used to improve diagnostic confidence. [38] [39] [40] The numerous advantages of FDG-PET imaging include a higher spatial resolution in comparison to conventional nuclear medicine modalities, fast examination time (result available within 1-2 hours after tracer administration), the ability to differentiate between hematopoietic bone marrow and activated white blood cells (WBCs), and potential application to treatment monitoring. 41 Additionally, the high spatial and contrast resolution of FDG-PET can distinguish soft tissue from osteomyelitis, and the absence of artifacts from metallic implants allows the imaging of patients with suspected infection in hip and knee prostheses. [42] [43] [44] A negative result of PET study essentially rules out osteomyelitis because of its high sensitivity in detecting infection; however, this may lead to increased false-positive results. 45, 46 A drawback of FDG-PET is the lack of anatomic landmarks, which may make it difficult to assign lesions to a particular structure. Integrated PET-CT scans can be used for functional-morphologic correlation. 39 The reported sensitivity and specificity for PET diagnosis of osteomyelitis range from 95% to 100% and 86% to 95%, respectively. 46, 47 The accuracy of FDG-PET in evaluating prosthetic joint infections, however, is higher in hip prostheses than in knee prostheses, perhaps because attenuation correction in imaging knee prostheses can introduce artifacts that lead to false-positive results. 48 Reported values for sensitivity, specificity, and accuracy of FDG-PET imaging for detecting infections are 90%, 89 50 During triple-phase imaging, positive signs of osteomyelitis are considered through the combined detection of focal hyperfusion immediately following contrast injection, focal hyperemia in the blood pool phase, and focal increases in bone uptake on delayed images. 50 Furthermore, the bone scan can alleviate image artifacts, which are found by CT or MRI in patients with existing implants or prostheses. 9 However, [ 99m Tc] MDP imaging only denotes regions of active bone turnover and, therefore, cannot discriminate osteomyelitis from other causes of increased local bone remodeling. 9 Therefore, specificity of this technique decreases in patients with underlying skeleton conditions, which may otherwise induce a positive finding on the bone scan. 50 Gallium-67 imaging can be used in conjunction with the bone scan to increase accuracy of detection, but the use of multiple isotopes over several days of imaging can be limiting. 50 Planar scintigraphy can be further improved using 3D SPECT imaging; however, the same caveats regarding specificity still can limit SPECT imaging of [ 99m Tc]MDP imaging in osteomyelitis. 35 Inflammation is the body's early response to injury (and infection) and involves delivery of leukocytes to the infected area where they can clear infectious agents and degrade necrotic tissues. Therefore, scintigraphy using ex vivo 111 In-oxine-radiolabeled leukocytes has been widely used as the gold standard for imaging the inflammation process. 9, 21, 23, 37 The leukocytes are radiolabeled and reinjected into the patient where they become distributed in the intravascular space. Patients then typically receive their scan 4-24 hours postinjection. This lapse gives time for blood pool activity to decrease and improves image quality. An area of increased activity is indicative of inflammation and infection, and Indium-111-labeled leukocyte ( 111 In-L) scintigraphy is the method of choice for localizing osteomyelitis. However, using radiolabeled leukocytes in this capacity also has associated challenges, because there is always the question of whether the radiolabeled cells remain viable and there is also the loss of specificity associated with imaging a system as complicated as the leukocyte response to inflammation. Moreover, ex vivo labeling entails cumbersome isolation or reinjection of the cells, and this also involves significant radiation exposure and increased risk of infection to both the patient and the staff. 21, 23, 51 Therefore, alternative strategies have been developed, including the use of radiolabeled nanocolloids and introduction of radiolabeled antigranulocyte monoclonal antibodies (MAbs), with the aim of addressing some of these issues.
Nuclear medicine techniques for diagnosis of osteomyelitis
Imaging bone inflammation with 99m
Tc-labeled nanocolloids ( 99m Tc-NCs) offers several advantages over 111 In-L scintigraphy, including lower radiation doses, ease of handling, and shorter preparation times. Biodistribution studies of 99m Tc-NCs in the rat have found that the blood activity in bone marrow imaging decreases from 14.5% at 30 minutes, 12.5% at 1 hour, and 12.4% at 3 hours, with 54.5% renal excretion after 24 hours. 52 In a study comparing three human albumin colloids and one antimony sulfide colloid, the nanometersized albumin-based colloid labeled with 99m Tc-Nanocoll ® (Nycomed Amersham Sorin S.R.L, Saluggia, Italy) had the highest bone marrow or spleen quotient and bone marrow or background quotient in patient scans. 53 Flivik et al 54 Tc-NCs, whereas diagnostic accuracy was 85% and 87%, respectively. When patients with slightly increased activity were regarded as being negative, the specificity increased to nearly 100%. 54 This is in agreement with a study by Papos et al, 55 which suggests both 99m Tc-NC and 99m
Tc-hexamethyl propylene amine oxime -labeled leukocyte scanning were of similar value for the detection of chronic posttraumatic osteomyelitis. However, leukocyte scintigraphy seemed to characterize the grade of inflammation better than did nanocolloid scintigraphy, with good correlation between the leukocyte scanning data and laboratory and bacteriologic data. Another comparative study found nanocolloid and IgG scans have a similar degree of sensitivity (95%) and specificity (100%) in the detection of focal inflammatory processes but are nonspecific in detecting an infective focus. 56 On the other hand, Ooi et al 57 
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Besilesomab for imaging inflammation/infection in peripheral bone false positives in nanocolloid scans are due to the suspected localizing mechanism. It is thought that the nanometer-sized particles leak out from the vascular endothelium and basement membrane and enter into the extravascular space and may be taken up into the reticuloendothelial system. In this way, the inflammatory process accounts for the localization of nanocolloid lesions, regardless of the disease etiology. 56, 58 The introduction of radiolabeled MAbs was a step forward in osteomyelitis detection, and this area of research has been the subject of a number of review articles. 23, 24 The most commonly used MAbs are the Fab fragment of the immunoglobulin (Ig)G antibody directed against the glycoprotein cross-reactive antigen-90 (sulesomab) and an IgG antibody against normal cross-reactive antigen-95 (NCA-95; BW 250/183, besilesomab [Scintimun ® ; IBA Molecular Imaging, Dulles, JA]). As besilesomab has marketing approval in Europe, 59 this review will focus upon its use in imaging inflammation and infection to date. Tc and is marketed as a kit for radiopharmaceutical preparation under the brand name Scintimun. 59 The kit contains the reduced form of besilesomab (ie, disulfide bridges have been prereduced to the corresponding thiols). Tc]sodium pertechnetate, and this is introduced into the Scintimun kit. The kit contains stannous chloride, which reduces sodium pertechnetate to Tc (IV), and Tc (IV) is then able to bind to the free thiols of the reduced antibody (Figure 3 59 The applicant was CIS Bio International and key findings from the EMEA report are concisely presented here for completeness.
Pharmacological considerations
Extensive pharmacological data for [ 99m Tc]besilesomab were presented in an assessment report on the evaluation of [ 99m Tc] besilesomab for human use by the European Medicines Agency (EMEA).
Absorption
The pharmacokinetic (PK) profile of besilesomab was evaluated in cynomolgus monkeys after intravenous administration of 0.5 mg antibody/kg of besilesomab with decayed 99m Tc. As expected, serum levels were found to be highest (14.5 µg/mL) at 10 minutes postinjection (n = 2). Subsequently, distribution of the antibody was found to be complete within 20 minutes, and the half-life of the antibody was 31 hours (n = 2). In a related PK study, [ Tc) was administered intravenously to rats, and the radioactivity in blood, tissues, urine, and feces was measured at a range of time points between 1 and 48 hours after administration. At 1 hour, the highest levels of radioactivity were found in the blood, followed by the liver, kidneys, compact bone, and small intestine. Elimination from most organs was found to be biphasic (half-lives of the initial and terminal phases were 2-7 and ,100 hours, respectively). Plasma half-life was found to be 30-35 hours. 
Distribution and dosimetry
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Blazeski et al phase (5-24 hours). Besilesomab antibody-based half-lives and clearance rates agreed with the corresponding plasma radioactivity values, suggesting that the labeled product was stable in vivo. The biodistribution data, measured in this study as percentage of regional activity vs whole body activity, showed similar results for the liver: 1.5% of whole body activity for imaging at 6 hours and 1.6% at 24 hours. The corresponding data for the spleen were 3.0% at 6 hours and 2.3% at 24 hours. Dosimetry was calculated using the Medical Internal Radiation Dose (MIRD) system and is summarized in Table 1 59 
Metabolism and excretion
Like most antibodies, besilesomab is metabolized into amino acids during hepatic clearance. Therefore, in addition to the labeled antibody, total blood radioactivity also includes contributions from other radioactive species, such as antibody fragments, metabolites, and free 99m Tc. Each of these by-products is cleared from blood differently. Although the radioactivity associated with intact antibody will stay in the blood for a reasonable time (antibody half-life in plasma = 44.5 hours 59 ), metabolites, radioactive fragments, and free 99m Tc will clear more rapidly from blood and will accumulate in the kidneys and, ultimately, in the urine. In all studies, about 14% of the injected radioactivity was recovered in urine, which was only collected for 24 hours after administration. This radioactivity can be attributed to the elimination of free 99m Tc and labeled low-molecular-weight antibody fragments and small radiometabolites. In this report, no information about the fate of the injected radioactivity beyond 24 59 
Mechanism of action
The mechanism of accumulation of besilesomab at the site of infection and inflammation has not been fully elucidated. However, it has been suggested that it is mainly passive (increased vascular permeability) and partly active (migration of human granulocytes, carrying [ 99m Tc]besilesomab, to the infection and inflammation sites) because only 10%-20% of the injected radiolabeled antibody bind in vivo to human circulating granulocytes. Specific binding of besilesomab to already migrated and activated granulocytes may be the major part of the detection signal. 59 Besilesomab binds granulocytes that express NCA-95, but it has been shown that such binding does not significantly affect granulocyte-mediated functions (eg, enzyme release and pinocytosis). 60 Moreover, besilesomab does not get internalized into the cytoplasm. 61 
Imaging inflammation and infection in patients with suspected osteomyelitis using besilesomab
During the 15 years since the introduction of [
99m Tc] besilesomab, numerous clinical studies evaluating its effectiveness in diagnosing osteomyelitis have been reported (Table 2) . 29, 34, 47, 59, [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] [72] [73] These studies have also been the subject of review 20, 33, 51, 74, 75 and retrospective data analysis, 29, 76 and 80 inflammatory bowel disease, [81] [82] [83] and septic loosening of knee 84 or hip 85 endoprosthesis, although a detailed discussion of such uses extends beyond the scope of this report. Beyond diagnosis of infection and inflammation, bone marrow scintigraphy has been used to track bone metastases in cancer patients 86, 87 and has also been considered for radiotherapeutic applications. 88 Recently, an assessment report from the EMEA, in response to CIS Bio International's application for marketing authorization, summarizes data from 59 In this most recent and pivotal phase III trial involving 119 patients with suspected osteomyelitis, the agreement rate between the 2 methods was estimated to be 83% (lower 95% confidence interval limit: 80%); however, there was no adequate standard of truth (or acceptable surrogate) used in this trial, and so diagnostic parameters like sensitivity and specificity could not be calculated. The lack of standard of truth was addressed during post hoc analysis based on a surrogate, which was an evaluation by an expert panel of all data available from the study. The overall diagnostic performance of [ 99m Tc]besilesomab determined during this post hoc analysis (sensitivity, 76%; specificity, 69%) was similar to that of the previous analysis based on the investigator diagnosis at 1 month (75% and 72%, respectively).
The data presented in Table 2 support clinical trial data from the EMEA report 59 about the apparent relationship between injected dose of [ Tc]besilesomab bone scintigraphy alone resulted in a specificity of 60% and sensitivity of 66%. Interpreting scintigraphy in conjunction with the SPECT scan resulted in improved sensitivity, whereas specificity was found to be lower (specificity, 55%; sensitivity, 89%). However, marked improvement in both parameters was observed when scintigraphy data were interpreted with SPECT and CT (specificity, 73%; sensitivity, 89% Tc]besilesomab and were scanned at 4 hours and 20-24 hours postinjection. In many cases, the scan was successful in revealing osteomyelitis. For example, the scan shown in Figure 4 was taken for a patient with a history of arthrodesis of the right ankle joint and subsequent chronic pain. The scan suggests infection, and indeed, in this case, chronic osteomyelitis was confirmed by biopsy.
However, of the 20 patients with suspected peripheral osteomyelitis, four false-positive and one false-negative findings were also observed, giving a specificity of 64% and sensitivity of 89%. These false-positive and false-negative results support the conclusions of a number of groups that scintigraphy is a powerful tool when used in conjunction with other modern imaging modalities, such as MRI or CT, and histologic examinations. 9, 29, 76 Finally, Guhlmann et al 47 Figure 5 ). Fifty-one patients who previously had a [ 99m Tc]MDP bone scan were investigated, and two expert readers analyzed the data. They concluded that although both methods were suitable for diagnosis of chronic osteomyelitis in the peripheral skeleton, FDG-PET was superior (accuracy, 96% vs 96%; sensitivity, 100% vs 97%; and specificity, 95% vs 95%) to [ 99m Tc]besilesomab (accuracy, 82% vs 88%; sensitivity, 86% vs 92%; and specificity, 77% vs 82%). The main difference between the two imaging agents in this study was that FDG allowed more reliable distinction between osteomyelitis and infection of the surrounding soft tissue. 
Conclusion
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